Study to Evaluate Adverse Events and Movement of Intravenously (IV) Infused ABBV-787 in Adult Participants With Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
← catalyst calendarSponsored by AbbVie (industry) · ABBV — their whole pipeline →.
Phase
Phase 1
Status
Terminated
Study type
Interventional
Design
Na · None · Treatment
Enrollment
36actual
Sites
24
Countries
Australia, Israel, Japan +2
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
Strategic considerations
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-11-13 | actual | When the study began enrolling |
| Primary completion | 2025-02-25 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-02-25 | actual | The whole study's end, after follow-up |
| First posted | 2023-10-05 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-03-06 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Acute Myeloid Leukemia
Intervention
- Drug: ABBV-787
Primary outcomes
what the primary-completion date above is the date OFNumber of Participants with Adverse Events (AE)
measured Up to Approximately 3 Years
Maximum Tolerated Dose (MTD) Based on Dose-Limiting Toxicities (DLT)
measured Up to approximately 28 Days
Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed